Volume 2, Issue 23, 06/08/2010
Why are patients with genetic defects to the hemojuvelin (HJV) gene at an increased risk for developing iron toxicity or hemochromatosis?
The previous two newsletter publications dedicated to the topic of pharmacogenetics provided a review of the common genetic defects or polymorphisms associated with an increased risk for the development of hemochromatosis and the mechanism of iron toxicity specifically in patients with Hereditary Hemochromatosis. This newsletter publication will focus on the mechanism involved in patients with Juvenile Hemochromatosis or Hemochromatosis Type 2A that predisposes patients to increased or excessive iron absorption.
......To read the full answer please LOGIN or SUBSCRIBE NOW.
Copyright 2012 Pharmacology Weekly, Inc. All Rights Reserved. |
